PET Radiomics and Response to Immunotherapy in Lung Cancer: A Systematic Review of the Literature.
PD-L1
PET
immunotherapy
lung cancer
response to therapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
20 Jun 2023
20 Jun 2023
Historique:
received:
09
05
2023
revised:
12
06
2023
accepted:
19
06
2023
medline:
28
6
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
epublish
Résumé
The aim of this review is to provide a comprehensive overview of the existing literature concerning the applications of positron emission tomography (PET) radiomics in lung cancer patient candidates or those undergoing immunotherapy. A systematic review was conducted on databases and web sources. English-language original articles were considered. The title and abstract were independently reviewed to evaluate study inclusion. Duplicate, out-of-topic, and review papers, or editorials, articles, and letters to editors were excluded. For each study, the radiomics analysis was assessed based on the radiomics quality score (RQS 2.0). The review was registered on the PROSPERO database with the number CRD42023402302. Fifteen papers were included, thirteen were qualified as using conventional radiomics approaches, and two used deep learning radiomics. The content of each study was different; indeed, seven papers investigated the potential ability of radiomics to predict PD-L1 expression and tumor microenvironment before starting immunotherapy. Moreover, two evaluated the prediction of response, and four investigated the utility of radiomics to predict the response to immunotherapy. Finally, two papers investigated the prediction of adverse events due to immunotherapy. Radiomics is promising for the evaluation of TME and for the prediction of response to immunotherapy, but some limitations should be overcome.
Identifiants
pubmed: 37370869
pii: cancers15123258
doi: 10.3390/cancers15123258
pmc: PMC10296704
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Radiol Oncol. 2020 Jul 29;54(3):285-294
pubmed: 32726293
CA Cancer J Clin. 2022 Jul;72(4):333-352
pubmed: 34902160
Cancers (Basel). 2022 Nov 30;14(23):
pubmed: 36497415
Cancers (Basel). 2022 Dec 11;14(24):
pubmed: 36551581
Mod Pathol. 2019 Mar;32(3):367-375
pubmed: 30297881
JAMA Oncol. 2019 Dec 1;5(12):1749-1768
pubmed: 31560378
EJNMMI Res. 2023 Jan 22;13(1):4
pubmed: 36682020
Phys Med. 2021 Mar;83:108-121
pubmed: 33765601
Front Oncol. 2021 Mar 29;11:633176
pubmed: 33854969
Nat Rev Clin Oncol. 2017 Dec;14(12):749-762
pubmed: 28975929
J Clin Med. 2020 May 06;9(5):
pubmed: 32384677
Sensors (Basel). 2022 Jul 04;22(13):
pubmed: 35808538
United European Gastroenterol J. 2016 Apr;4(2):257-63
pubmed: 27087955
Cancers (Basel). 2022 Feb 16;14(4):
pubmed: 35205733
Insights Imaging. 2020 Aug 12;11(1):91
pubmed: 32785796
Front Oncol. 2021 Nov 17;11:769272
pubmed: 34868999
Front Immunol. 2022 Nov 17;13:994917
pubmed: 36466929
Br J Cancer. 2021 Jul;125(2):229-239
pubmed: 33828255
Nat Commun. 2015 Mar 26;6:6692
pubmed: 25809635
Cancers (Basel). 2020 Oct 07;12(10):
pubmed: 33036490
Nat Rev Clin Oncol. 2021 Jun;18(6):345-362
pubmed: 33580222
Front Oncol. 2021 Dec 16;11:789014
pubmed: 34976829
BMJ. 2018 Nov 08;363:k4226
pubmed: 30409774
Cell Physiol Biochem. 2015;37(4):1560-71
pubmed: 26513143
J Thorac Dis. 2019 Jan;11(Suppl 1):S25-S36
pubmed: 30775025
Cancers (Basel). 2020 May 05;12(5):
pubmed: 32380754
Open Med. 2009;3(3):e123-30
pubmed: 21603045
Immunity. 2016 Aug 16;45(2):358-73
pubmed: 27496729
J Thorac Dis. 2018 Feb;10(2):617-620
pubmed: 29607123
Lancet Digit Health. 2019 Jul;1(3):e106-e107
pubmed: 33323257
Radiology. 2020 May;295(2):328-338
pubmed: 32154773
Front Oncol. 2022 Aug 11;12:945102
pubmed: 36033435
Immunity. 2016 May 17;44(5):1052-68
pubmed: 27192569
Nucl Med Commun. 2019 Aug;40(8):802-807
pubmed: 31045745
J Immunother Cancer. 2021 Jun;9(6):
pubmed: 34135101
Transl Lung Cancer Res. 2021 Feb;10(2):1186-1199
pubmed: 33718055
Theranostics. 2020 Aug 29;10(23):10838-10848
pubmed: 32929383
Biomark Res. 2023 Jan 25;11(1):10
pubmed: 36694213
J Immunother Cancer. 2022 Sep;10(9):
pubmed: 36180071
Radiol Artif Intell. 2020 Jan 29;2(1):e190063
pubmed: 33937811
Immunity. 2007 Oct;27(4):670-84
pubmed: 17950003
Acad Radiol. 2020 Feb;27(2):171-179
pubmed: 31147234
Front Oncol. 2021 Dec 17;11:737368
pubmed: 34976794
Diagnostics (Basel). 2022 Oct 10;12(10):
pubmed: 36292136
Eur J Nucl Med Mol Imaging. 2020 May;47(5):1168-1182
pubmed: 31807885
J Clin Med. 2022 Mar 21;11(6):
pubmed: 35330068
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Nat Rev Cancer. 2002 Nov;2(11):862-71
pubmed: 12415256
Curr Oncol. 2022 Mar 09;29(3):1828-1839
pubmed: 35323350
Eur J Nucl Med Mol Imaging. 2022 Nov;49(13):4692-4704
pubmed: 35819498
Front Immunol. 2022 Apr 29;13:859323
pubmed: 35572597